BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit
SEND @SOT 2023: Same, but different
Marc Ellison
A look at the main SEND discussion points at SOT 2023
SEND Blog
BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit
Is there really that much to say about SEND?
Marc Ellison
When it comes to SEND “What is there to talk about?”, actually quite a lot.
BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit
Who uses the CoDEx document anyway?
Marc Ellison
The Confirmed Data Endpoints for Exchange (CoDEx) is CDISC’s method of addressing the scope for SEND, down to the individual endpoints.
BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit
Are you ready for a tighter standard?
Marc Ellison
As work continues on the content and updates for SEND 4.0, there’s a definite change in approach in an effort to make study representation more uniform, and to give implementors much clearer direction.
BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionSENDSEND Advantage ServicesSensible SENDSubmit
How creative should we be with SEND?
Marc Ellison
Can a certain study or data type be represented in SEND? The more ‘creative’ we need to get to place data in SEND, then potentially the less useful it is.
BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit
SEND in 2023
Marc Ellison
What the year ahead looks like for the world of SEND.
Stay up to Date
Get expert tips, industry news, and fresh content delivered to your inbox.
